AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:08 2024-04-25 am EDT 5-day change 1st Jan Change
12,026 GBX +5.94% Intraday chart for AstraZeneca PLC +10.72% +13.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Drops Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Drop in Afternoon Trading MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump MT
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade Alphavalue
FTSE 100 shakes off red-hot US inflation gauge AN
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco... Our Logo
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
ASTRAZENECA : UBS maintains a Sell rating ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday MT
The specter of stagflation rears its ugly head again Our Logo
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15 DP
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data MT
ASTRAZENECA : Jefferies sticks Neutral ZD
ASTRAZENECA : JP Morgan remains its Buy rating ZD
FTSE 100 hits high on offer for Anglo American AN
Transcript : AstraZeneca PLC, Q1 2024 Earnings Call, Apr 25, 2024
AstraZeneca Q1 Core Earnings, Revenue Increase -- Shares Jump Premarket MT
ANALYST RECOMMENDATIONS : Meta Platforms, UPS, Boeing, Chipotle, Dell Technologies... Our Logo
AstraZeneca Earnings, Sales Rise, Beating Forecasts -- Update DJ
European Midday Briefing : Mood Cautious Ahead of More U.S Tech, Key Data DJ
London rises ahead of US GDP data Our Logo
AstraZeneca: strong sales growth in Q1 CF
AstraZeneca upbeat as cancer drugs underpin sales growth AN
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.1 USD
Average target price
161.1 USD
Spread / Average Target
+14.14%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca Says Phase 3 Trial Interim Data Show Imfinzi Plus Chemotherapy Improves Pathologic Response in Lung Cancer Patients